Table 3 Clinical and immunological characteristics of the study subjects, at JUSH from July-September 2012
Variables | Females N (%) | Males N (%) | Total N (%) |
|---|---|---|---|
WHO clinical stage | |||
Stage I | 56(62.2) | 34(37.8) | 90(24.9) |
Stage II | 80(56.7) | 61(43.3) | 141(39.1) |
Stage III | 66(64.7) | 36(35.3) | 102(28.3) |
Stage IV | 10(35.7) | 18(64.3) | 28(7.8) |
Opportunistic infections | |||
TB | 12(46.2) | 14(53.8) | 26(7.2) |
Chronic GE | 6(50) | 6(50) | 12(3.3) |
Pneumonia | 1(20) | 4(80) | 5(1.4) |
Candidiasis | 4(80) | 1(20) | 5(1.4) |
No Total | 189(60.4) 212(58.7) | 124(39.6) 149(41.3) | 313(86.7) 361(100) |
Co- morbidities | |||
HTN | 2(100) | 0(0) | 2(0.5) |
DM | 0(0) | 2(100) | 2(0.5) |
CLD | 2(100) | 0(0) | 2(0.5) |
No Total | 208(58.6) 212(58.7) | 147(41.4) 149(41.3) | 355(98.3) 361(100) |
Immunologic stage | |||
CD4 ≥ 500 | 53(69.7) | 23(30.3) | 76(21.1) |
CD4 200-499 | 127(57.7) | 93(42.3) | 220(60.9) |
CD4 < 200 | 32(49.2) | 33(50.8) | 65(18.0) |